Barely Significant
← all excerpts

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.

ESMO Open · 2021 · PMC8437777 · PMID 34509804

Europe PMCDOI
1
hedged sentence
0.1500
closest p · 3.0× alpha
0.1500
boldest claim

The sentences

showed a trendP = 0.15not close (p > 0.1)
In univariate analysis, those on abiraterone showed a trend toward increased risk for composite primary CV outcome [hazard ratio (HR) 1.17; 95% confidence interval (CI) 0.94-1.47; P = 0.15].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.